Clinical OMICs Magazine: Volume 2

Promoting Wellness and Demystifying Disease: The 100K Project

We believe that a longitudinal, Framingham-like study of 100,000 well individuals (hereafter termed the 100K project) and their dynamical data clouds could transform medicine...
Source: decade3d/Getty Images

Metabolite Signature to Diagnose Typhoid Fever Identified

Using mass spectrometry methods, the scientists created a predictive model for the disease based on metabolites found in the blood.
Source: lolloj/Getty Images

Epigenomic Analysis of Schizophrenia Helps Underscore Genetic Causes

New study makes advances in understanding how genetic risk factors alter gene function for schizophrenia.

Thermo Fisher Scientific Partners with Blueprint Medicines on Cancer CDx

Thermo Fisher Scientific plans to develop its Oncomine Dx Target Test as a companion diagnostic for Blueprint Medicines' BLU-667.
GenomeDx Biosciences has agreed to pay the U.S. federal government $1.99 million to settle allegations that it submitted false claims to Medicare for the Decipher post-operative genetic test for prostate cancer patients. [National Cancer Institute

GenomeDx to Pay $1.99M to Settle Medicare Billing Allegations

Company accused of submitting false claims to Medicare for the Decipher prostate cancer test between September 2015 and June 2017
A recent report estimates the global demand for PCR technologies in 2013 to be around $10.6 billion. [Caleb Foster -]

Expanding End-Use Segments Drive PCR Growth Worldwide

The polymerase chain reaction (PCR) has come a long way during the past three decades to become one of the fundamental platforms in life...

Predicine, Kintor Pharmaceuticals Launch Precision Oncology Partnership

Kintor will use Predicine’s expertise in genomics and molecular information to advance the development of its oncology pipeline
Source: dem10/ Getty Images

Researchers ID Disease-Causing Mutations in the Exome That Alter Gene Splicing

To help identify disease-causing variants in the genome, researchers developed a tool that works by producing artificial “minigenes.”
Paragon Genomics' CleanPlex next-generation sequencing (NGS) target enrichment technologies will be incorporated into Sophia Genetics’ SOPHiA AI Platform

Paragon’s CleanPlex Incorporated into Sophia Genetics’ AI Platform

Partnership designed to offer SOPHiA AI users accurate genomic detection and characterization of tumor alterations in a single test
Claritas Genomics

Claritas Genomics Ceases Operations, Five Years After Spinout

Genetic diagnostic lab, spun out of Boston Children’s Hospital in 2013, tells the New York State Department of Health that it has shut down.
Scroll Up